These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17380542)

  • 1. Non-inferiority trial design for recurrent events.
    Cook RJ; Lee KA; Li H
    Stat Med; 2007 Nov; 26(25):4563-77. PubMed ID: 17380542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tests for multivariate recurrent events in the presence of a terminal event.
    Chen BE; Cook RJ
    Biostatistics; 2004 Jan; 5(1):129-43. PubMed ID: 14744832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size estimation for non-inferiority trials of time-to-event data.
    Crisp A; Curtis P
    Pharm Stat; 2008; 7(4):236-44. PubMed ID: 17583558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the horizon: can bisphosphonates prevent bone metastases?
    Coleman R
    Breast; 2007 Dec; 16 Suppl 3():S21-7. PubMed ID: 17988867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-stage design of clinical trials involving recurrent events.
    Cook RJ; Bergeron PJ; Boher JM; Liu Y
    Stat Med; 2009 Sep; 28(21):2617-38. PubMed ID: 19579215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conditional analysis of mixed Poisson processes with baseline counts: implications for trial design and analysis.
    Cook RJ; Wei W
    Biostatistics; 2003 Jul; 4(3):479-94. PubMed ID: 12925513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.
    Costa L
    Breast; 2007 Dec; 16 Suppl 3():S16-20. PubMed ID: 18032044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A copula-based mixed Poisson model for bivariate recurrent events under event-dependent censoring.
    Cook RJ; Lawless JF; Lee KA
    Stat Med; 2010 Mar; 29(6):694-707. PubMed ID: 20146240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy of bone metastases in breast cancer patients.
    Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
    Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robust tests for treatment effects based on censored recurrent event data observed over multiple periods.
    Cook RJ; Wei W; Yi GY
    Biometrics; 2005 Sep; 61(3):692-701. PubMed ID: 16135020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size calculations for comparative clinical trials with over-dispersed Poisson process data.
    Matsui S
    Stat Med; 2005 May; 24(9):1339-56. PubMed ID: 15568188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
    Machado M; Cruz LS; Tannus G; Fonseca M
    Clin Ther; 2009 May; 31(5):962-79. PubMed ID: 19539097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rank-based tests for non-inferiority and equivalence hypotheses in multi-centre clinical trials using mixed models.
    Rashid MM
    Stat Med; 2003 Jan; 22(2):291-311. PubMed ID: 12520563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for one-sided testing of the difference between proportions and sample size considerations related to non-inferiority clinical trials.
    Dann RS; Koch GG
    Pharm Stat; 2008; 7(2):130-41. PubMed ID: 17526060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging strategies in bone health management for the adjuvant patient.
    Coleman RE
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S11-6. PubMed ID: 18068485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust non-parametric one-sample tests for the analysis of recurrent events.
    Rebora P; Galimberti S; Valsecchi MG
    Stat Med; 2010 Dec; 29(30):3137-46. PubMed ID: 21170908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A general approach for sample size and statistical power calculations assessing of interventions using a mixture model in the presence of detection limits.
    Nie L; Chu H; Cole SR
    Contemp Clin Trials; 2006 Oct; 27(5):483-91. PubMed ID: 16769254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A framework for two-stage adaptive procedures to simultaneously test non-inferiority and superiority.
    Koyama T; Sampson AR; Gleser LJ
    Stat Med; 2005 Aug; 24(16):2439-56. PubMed ID: 15977285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.